uniQure
QURE

$8.34

2.74%

Market Cap: 405M

About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Employees: 480

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

0

News positive %

of 12 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 34

10% less funds holding

Funds holding: 141 [Q4 2023] → 127 (-14) [Q1 2024]

17.16% less ownership

Funds ownership: 84.6% [Q4 2023] → 67.44% (-17.16%) [Q1 2024]

25% less call options, than puts

Call options by funds: $5.46M | Put options by funds: $7.26M

38% less capital invested

Capital invested by funds: $274M [Q4 2023] → $170M (-$104M) [Q1 2024]

44% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 32

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6

28%

downside

Avg. target

$17.14

106%

upside

High target

$25

200%

upside

7 analyst ratings

4 positive

57%

3 neutral

43%

0 negative

0%

Cantor Fitzgerald Kristen Kluska	188%upside $24	Overweight Reiterated	16 Jul 2024
HC Wainwright & Co. Patrick Trucchio	200%upside $25	Buy Reiterated	9 Jul 2024
HC Wainwright & Co. Patrick Trucchio	200%upside $25	Buy Reiterated	8 May 2024
Mizuho Uy Ear	28%downside $6	Neutral Maintained	8 May 2024
Mizuho Uy Ear	16%downside $7	Neutral Maintained	4 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about QURE published over the past 30 days

Zacks Investment Research

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?

The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

What Led To A 150% Rise In UniQure Stock In A Week?

uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE stock can be attributed to the positive outcome from its phase I-II clinical trials of AMT-130 for Huntington's disease.

What Led To A 150% Rise In UniQure Stock In A Week?

Zacks Investment Research

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet

The consensus price target hints at a 195.8% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet

Zacks Investment Research

uniQure (QURE) Soars on New Huntington's Disease Study Data

uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.

uniQure (QURE) Soars on New Huntington's Disease Study Data

Zacks Investment Research

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company plans to meet with the FDA in H2 2024 to discuss the possible Accelerated Approval pathway of AMT-130 for the treatment of patients with Huntington's Disease. 36-month data from the phase 1/2 studies using AMT-130 for the treatment of patients with Huntington's Disease is expected in mid-2025.

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Zacks Investment Research

Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)

uniQure (QURE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)

Why Is uniQure (QURE) Stock Up 51% Today?

UniQure (NASDAQ: QURE ) stock is on the rise Tuesday after the company provided investors with interim clinical data from a PhaseI/II clinical trials for AMT-130. These clinical trials are evaluating the use of AMT-130 as a treatment for Huntington's Disease.

Why Is uniQure (QURE) Stock Up 51% Today?

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted external control ~

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

See News Rankings